Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission
暂无分享,去创建一个
L. Rybicki | M. Kalaycio | B. Pohlman | E. Copelan | R. Sobecks | S. Andresen | R. Dean | J. Chan | J. Sweetenham | B. Bolwell | L. Sproat | S. Tench | Shawnda Tench
[1] Hisashi Sakamaki,et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.
[2] A. Keating,et al. Is there a role for autotransplants in AML in first remission? , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] F. Lo Coco,et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Augustin Ferrant,et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.
[5] M. Björkholm,et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. , 2006, Haematologica.
[6] T. Naoe,et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission , 2005, Cancer.
[7] I. Haznedaroglu,et al. Cytarabine-induced fever complicating the clinical course of leukemia , 2005, Anti-cancer drugs.
[8] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Pashos,et al. Economic burden of acute myeloid leukemia: a literature review. , 2004, Cancer treatment reviews.
[10] A. Goldstone,et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial , 2002, British journal of haematology.
[11] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[12] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[13] M. Horowitz,et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. , 2000, Blood.
[14] J. Sierra,et al. No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission , 2000, British journal of haematology.
[15] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[16] J. Reiffers,et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. , 1992, Bone marrow transplantation.